Please note: We are currently experiencing some performance issues across the site, and some pages may be slow to load. We are working on restoring normal service soon. Importing new articles from Word documents is also currently unavailable. We apologize for any inconvenience.

loading page

Cardiogenic shock on 5-fluoruracile: a rare, fulminant and transient disease that deserves attention
  • +3
  • Tiphaine Lambert,
  • Valérie Boige,
  • Patrick Bruneval,
  • Agnès Lillo-Lelouet,
  • Daniel Orbach,
  • Mariana Mirabel
Tiphaine Lambert
Institut Curie

Corresponding Author:[email protected]

Author Profile
Valérie Boige
Insitut Gustave Roussy, Villejuif, France
Author Profile
Patrick Bruneval
Assistance Publique - Hopitaux de Paris
Author Profile
Agnès Lillo-Lelouet
Assistance Publique - Hopitaux de Paris
Author Profile
Daniel Orbach
Institut Curie
Author Profile
Mariana Mirabel
Assistance Publique - Hopitaux de Paris
Author Profile

Abstract

Five-fluorouracil (5-FU) and platins remain a first line treatment in oncology with a potential of cardiovascular toxicity. We identified two cases of acute severe cardiac toxicity treated with a combination of 5FU (different production batch) and platins at three months interval at two different institutions referred to our cardio-oncology services. Both cases had similar clinical presentation, favorable outcomes and identical cardiac magnetic imaging scans at follow-up. Mechanism was direct myocardial toxicity in the case with endomyocardial biopsy. Circulatory support as a bridge to recovery should be considered in the case of untreatable cardiogenic shock likely due to 5-FU.